Research Topics
Genomes and GenesSpecies | Mario CazzolaSummaryAffiliation: University of Pavia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Novel genes, proteins, and inherited disorders of iron overload: iron metabolism is less boring than thoughtMario Cazzola
Haematologica 87:115-6. 2002
Erythropoietin pathophysiology and erythropoietin deficiency anemiaMario Cazzola
University of Pavia Medical School, Pavia, Italy
Hematol J 5:S100-3. 2004
Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutationMario Cazzola
Department of Hematology, University of Pavia Medical School, Pavia, Italy
Blood 100:4236-8. 2002..This observation is relevant to genetic counseling, emphasizing the importance of gene-based diagnosis...
Prognostic classification and risk assessment in myelodysplastic syndromesMario Cazzola
Department of Hematology Oncology, Medical School, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Hematol Oncol Clin North Am 24:459-68. 2010..WPSS predicts survival and leukemia progression at any time during follow-up, and may therefore be used for implementing risk-adapted treatment strategies...
Pyruvate kinase deficiencyMario Cazzola
University of Pavia Medical School, Division of Hematology, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Haematologica 90:1-2. 2005
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin productionMario Cazzola
Division of Haematology, University of Pavia Medical School, Pavia, Italy
Br J Haematol 122:386-93. 2003..Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective...
Erythropoietin therapy: need for rationality and active surveillanceMario Cazzola
University of Pavia Medical School, Division of Hematology, IRCCS Policlinico S. Matteo, Pavia, Italy
Haematologica 88:601-5. 2003
Role of ferritin and ferroportin genes in unexplained hyperferritinaemiaMario Cazzola
Department of Haematology, University of Pavia Medical School, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Best Pract Res Clin Haematol 18:251-63. 2005..These genetic disorders should be taken into account in the differential diagnosis of unexplained hyperferritinaemia...
Classification and prognostic evaluation of myelodysplastic syndromesMario Cazzola
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia Medical School, Italy
Semin Oncol 38:627-34. 2011..Since comorbidities have a significant impact on the outcome of patients with MDS, accounting for both disease status and comorbid conditions considerably improves risk stratification...
Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemiaMario Cazzola
Department of Hematology, University of Pavia Medical School and Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico S Matteo, Pavia, Italy
Blood 101:1996-2000. 2003..These findings suggest that most of the iron deposited in perinuclear mitochondria of ring sideroblasts is present in the form of MtF and that this latter might be a specific marker of sideroblastic anemia...
Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3)Mario Cazzola
Division of Haematology, University of Pavia Medical School, IRCCS Policlinico S Matteo, Pavia, Italy
Br J Haematol 119:539-46. 2002..Heterozygosity for the ferroportin Val 162 deletion represents the prototype of selective reticuloendothelial iron overload, and should be taken into account in the differential diagnosis of hereditary or congenital hyperferritinaemias...
Myelodysplastic/myeloproliferative neoplasmsMario Cazzola
Department of Hematology Oncology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Hematology Am Soc Hematol Educ Program 2011:264-72. 2011..It is hoped that these advances will soon translate into improved therapeutic approaches...
Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?Mario Cazzola
Department of Hematology, University of Pavia, Italy
Nat Clin Pract Oncol 1:22-3. 2004
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlationsEmanuela Boveri
Department of Surgical Pathology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Br J Haematol 140:162-8. 2008..003), and anaemia (P < 0.001) independently correlated with MVD. In summary, this study indicates that assessment of BM angiogenesis, as measured by MVD, may be a useful additional tool in the histopathological definition of CMD...
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Luca Malcovati
Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Haematologica 96:1433-40. 2011..We, therefore, studied the relationship between severity of anemia and outcome in myelodysplastic syndrome patients...
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosisFrancesco Passamonti
Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy
Blood 111:3383-7. 2008..In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF...
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disordersElisa Rumi
Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia School of Medicine, Pavia, Italy
Cancer 107:2206-11. 2006..Thus, a genetic predisposition to acquisition of JAK2 (V617F) is inherited in families with myeloproliferative disorders...
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeMatteo G Della Porta
Department of Hematology Oncology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Haematologica 96:441-9. 2011..Accounting for both disease status by means of the WPSS and comorbidity through the MDS-CI considerably improves risk stratification in myelodysplastic syndromes...
Blast phase of essential thrombocythemia: A single center studyFrancesco Passamonti
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Hematol 84:641-4. 2009..JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. The outcome of patients is poor whatever the treatment used...
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipationElisa Rumi
Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Viale Golgi 49, 27100 Pavia, Italy
J Clin Oncol 25:5630-5. 2007..However, familial clustering is reported. The purpose of this study was to assess the prevalence and the clinical phenotype of familial CMDs, and to study the anticipation of disease onset in successive generations...
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision makingLuca Malcovati
Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy
J Clin Oncol 23:7594-603. 2005..MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable...
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosisLuca Malcovati
Department of Hematology Oncology, University of Pavia and Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico IRCCS, Policlinico San Matteo, Pavia, Italy
Blood 114:3538-45. 2009....
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersFrancesco Passamonti
Department of Hematology, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Blood 107:3676-82. 2006..This exemplifies a novel paradigm in which a somatic gain-of-function mutation is initially responsible for clonal expansion of hematopoietic cells and later for their abnormal trafficking via an activated cell progeny...
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaFrancesco Passamonti
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Med 117:755-61. 2004..To assess life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia...
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemiaRosangela Invernizzi
Institute of Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
Eur J Haematol 76:494-501. 2006..The detection of survivin-deregulated expression may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments...
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromesMatteo Giovanni Della Porta
Department of Hematology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
J Clin Oncol 27:754-62. 2009..We studied bone marrow (BM) histologic abnormalities in myelodysplastic syndromes (MDS) classified according to WHO criteria to determine their clinical correlates and prognostic value...
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasmElisa Rumi
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Hematol 86:974-9. 2011....
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromesErica Travaglino
Department of Internal Medicine, University of Pavia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy
Eur J Haematol 80:216-26. 2008..In MDS, the detection of MMP deregulated expression may be important also from the clinical point of view: it may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments...
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myelomaSilvia Mangiacavalli
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Hematol 88:102-6. 2013..87) when compared to bortezomib-naive patients. Thrombocytopenia was the most common AE overall. In conclusion, B-MuD is an effective and well tolerated combination in relapsed MM patients even in advanced disease phase...
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disordersFrancesco Passamonti
Division of Hematology, University of Pavia Medical School and IRCCS Policlinico S. Matteo, Pavia, Italy
Haematologica 88:1123-9. 2003..Thus, enumeration of circulating CD34-positive cells may be useful in the work-up of patients with myeloproliferative disorders...
Long-term follow-up of young patients with essential thrombocythemia treated with pipobromanFrancesco Passamonti
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
Ann Hematol 83:495-7. 2004
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati
Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
J Clin Oncol 25:3503-10. 2007....
Leukemic transformation of polycythemia vera: a single center study of 23 patientsFrancesco Passamonti
Division of Hematology, IRCCS San Matteo Polyclinic, University of Pavia, Pavia, Italy
Cancer 104:1032-6. 2005..Acute leukemia (AL) may occur as rare and late event of polycythemia vera (PV)...
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasmsMarzia Varettoni
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Blood 121:2522-8. 2013..In this latter condition, MYD88 (L265P) is associated with greater disease burden and higher risk of disease progression, and the mutation may therefore also represent a useful prognostic marker...
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsLuca Malcovati
Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy
Blood 118:6239-46. 2011..Furthermore, SF3B1 mutations are independent predictors of favorable clinical outcome, and their incorporation into stratification systems might improve risk assessment in MDS...
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasiaElisa Rumi
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Am J Hematol 81:124-7. 2006..This case points to the importance of suspecting pulmonary EMH when unexplained progressive dyspnea occurs in a patient with MMM. Early recognition of pulmonary EMH may prevent PH and favor a better response to therapy...
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)Francesco Passamonti
Department of Hematology Oncology, University of Pavia and Fondazione, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy
Blood 115:1703-8. 2010..81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making...
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisVittorio Rosti
Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
PLoS ONE 5:e15277. 2010..Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment...
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasmsDaniela Pietra
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Haematologica 96:607-11. 2011..In 3 cases carrying double MPL mutations, deep sequencing analysis showed identical load and location in cis of the paired lesions, indicating their simultaneous occurrence on the same chromosome...
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and TreatmentFrancesco Passamonti
Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Blood 120:1197-201. 2012....
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disordersFrancesco Passamonti
Division of Haematology, University of Pavia Medical School and IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
Br J Haematol 126:650-6. 2004..From a clinical viewpoint, neutrophil CD177 mRNA overexpression is rather a marker of abnormal neutrophil production and/or release in patients with CMD...
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationFrancesco Passamonti
Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo, Pavia, Italy
Blood 110:485-9. 2007..A relationship was found between JAK2 (617V>F) and fetal loss (P = .05). This study indicates that patients carrying the JAK2 (617V>F) mutation have higher risk of developing pregnancy complications...
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disordersDaniela Pietra
Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
Blood 111:1686-9. 2008..Moreover, a genetic predisposition to acquisition of different JAK2 mutations is inherited in families with myeloproliferative disorders...
Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophagesAnna Galli
Division of Haematology, University of Pavia Medical School and IRCCS Policlinico S Matteo, 27100 Pavia, Italy
Br J Haematol 127:598-603. 2004..Second, this observation supports the hypothesis that reticuloendothelial iron overload in patients with ferroportin disease is caused by loss-of-function mutations in the SLC11A3 gene that mainly impair macrophage iron recycling...
Survivin expression in acute leukemias and myelodysplastic syndromesRosangela Invernizzi
Internal Medicine and Medical Oncology, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
Leuk Lymphoma 45:2229-37. 2004..Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death...
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Blood 117:2813-6. 2011..These findings suggest that, despite the phenotypical difference, the outcome of JAK2 exon 12 mutations-positive PV is similar to that of JAK2 (V617F)-positive PV...
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1Ilaria Ambaglio
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Haematologica 98:420-3. 2013..013). These observations suggest that patients with SF3B1 mutation have inappropriately low hepcidin levels, which may explain their propensity to parenchymal iron loading...
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapiesFrancesco Passamonti
Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Oncotarget 2:485-90. 2011..On the other hand, JAK inhibitors have not thus far shown disease-modifying activity therefore any other deduction on these new drugs seems premature...
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failureCristina Opasich
Department of Cardiology, Institute of Pavia, IRCCS Fondazione Salvatore Maugeri, Strada Ferrata 8, 27100 Pavia, Italy
Eur Heart J 26:2232-7. 2005..Anaemia is often observed in patients with chronic heart failure (CHF), and it may be associated with a worse prognosis. Aim of this study was to identify the individual mechanisms of anaemia in CHF patients...
Hematologic passport for athletes competing in endurance sports: a feasibility studyLuca Malcovati
Division of Hematology, University of Pavia Medical School and IRCCS Policlinico S. Matteo, Pavia, Italy
Haematologica 88:570-81. 2003..The hematologic passport should be used within a global strategy to deter blood doping...
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndromeMario Cazzola
Division of Haematology, University of Pavia Medical School, IRCCS Policlinico S Matteo, 27100 Pavia, Italy
Br J Haematol 116:667-70. 2002..A double-gradient denaturing gradient gel electrophoresis (DG-DGGE) method easily detected the above deletion...
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasmsMario Cazzola
Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy and
Blood 121:260-9. 2013..The assessment of SF3B1 mutation status may become innovative diagnostic and prognostic tools and the availability of spliceosome modulators opens novel therapeutic prospects...
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndromeIrene Dambruoso
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
Cancer Genet 205:285-94. 2012....
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasmsLuca Arcaini
Departments of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy
Blood 119:188-91. 2012..We conclude that the BRAF V600E mutation is present in all patients with HCL and that, in combination with clinical and morphologic features, represents a reliable molecular marker for this condition...
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudicesMario Cazzola
University of Pavia Medical School, Division of Hematology, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy. mario. it
Haematologica 89:137-8. 2004
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myelomaAlessandro Corso
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Universita di Pavia, Pavia, Italy
Am J Hematol 87:150-4. 2012..Am. J. Hematol. 2011. © 2011 Wiley Periodicals, Inc...
Hereditary hyperferritinaemia/ cataract syndromeMario Cazzola
Department of Hematology, University of Pavia Medical School, IRCCS Policlinico S. Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
Best Pract Res Clin Haematol 15:385-98. 2002..This exemplifies a new paradigm in which mutations in mRNA cis-acting elements may be responsible for phenotypic variability in disease states...
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of HematologyEmilio Paolo Alessandrino
Divisione di Ematologia, IRCCS Policlinico S. Matteo, Pavia, Italy
Haematologica 87:1286-306. 2002..INTERPRETATION AND CONCLUSIONS: Using evidence and consensus, recommendations for the treatment of MDS were issued. Statements were graded according to the strength of the supporting evidence and uncertainty was explicitly declared...
Myelodysplastic syndromes--coping with ineffective hematopoiesisMario Cazzola
University of Pavia Medical School, Pavia, Italy
N Engl J Med 352:536-8. 2005
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosisFrancesco Passamonti
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Br J Haematol 116:855-61. 2002..The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET...
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndromeMartin Jadersten
Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
J Clin Oncol 26:3607-13. 2008..To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS)...
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromesRamin Tehranchi
Department of Medicine, Division of Hematology, Karolinska Institutet, Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
Blood 106:247-53. 2005..In conclusion, aberrant MtF expression in RARS erythroblasts occurs at a very early stage of erythroid differentiation and is paralleled by an up-regulation of genes involved in this process...
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosisCarmela Lanzara
Dipartimento di Patologia Generale, II Universita di Napoli, Italy
Blood 103:4317-21. 2004..Mutations either generate premature termination codons or were missense substitutions, affecting highly conserved residues, relevant to the protein structure and/or function...
Genetic disorders of iron overload and the novel "ferroportin disease"Mario Cazzola
Haematologica 88:721-4. 2003
Mitochondrial ferritin: a new player in iron metabolismJim Drysdale
Department of Biochemistry, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
Blood Cells Mol Dis 29:376-83. 2002..The regulation of MtF expression and possible therapeutic applications of MtF in neurological disorders involving increased iron deposition are topics for future research...
Natural history of juvenile haemochromatosisMarco De Gobbi
Dipartimento di Scienze Cliniche e Biologiche, , Azienda Ospedaliera San Luigi, 10043 Orbassano, Turin, Italy
Br J Haematol 117:973-9. 2002..Our results clarify the natural history of the disease and are compatible with the hypothesis that the HFE2 gene has greater influence on iron absorption than other haemochromatosis-associated genes...
Genetic and clinical heterogeneity of ferroportin diseaseL Cremonesi
Unit of Genomics for the Diagnosis of Human Pathologies, IRCCS H San Raffaele, Milan, Italy
Br J Haematol 131:663-70. 2005..This condition should be considered not only in families with autosomal iron overload or hyperferritinaemia, but also in cases of unexplained hyperferritinaemia...
[Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]José Antonio García Erce
Servicio de Hematologia y Hemoterapia, Hospital Miguel Servet, P Isabel La Católica 1 3, 50009 Zaragoza, Spain
Med Clin (Barc) 127:55-8. 2006..This HHCS is associated with mutations in the gene of ferritin subunit L, located in chromosome 19. We describe 2 new families with HHCS, one of them presenting a new L-ferritin mutation (A37T: -Zaragoza-)...
Gene expression profiling of CD34+ cells in patients with the 5q- syndromeJacqueline Boultwood
LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK
Br J Haematol 139:578-89. 2007..This study suggests that several of the genes mapping to the CDR of the 5q- syndrome play a role in the pathogenesis of this disorder...
Myelodysplastic/myeloproliferative disordersLuca Malcovati
Haematologica 93:4-6. 2008
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemiaElisa Rumi
Leuk Lymphoma 48:805-7. 2007
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotypeAndrea Pellagatti
Leukaemia Research Fund (LRF) Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences (NDCLS, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Blood 108:337-45. 2006..This study provides important and new insights into the pathophysiology of MDS...
Practice guidelines for the therapy of primary myelodysplastic syndromes: a word of caution about their translation into clinical practiceMario Cazzola
Haematologica 87:1240-1. 2002
Respiratory infections and asthmaGirolamo Pelaia
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Italy
Respir Med 100:775-84. 2006..All these microbial agents probably interfere with complex immunological pathways, thus contributing to induce and exacerbate asthma in genetically predisposed individuals...
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disordersEmanuele Angelucci
Hematology Department and BMT Unit, Cancer Center Armando Businco, viale Edward Jenner, 09121 Cagliari, Italy
Haematologica 93:741-52. 2008....
Predicting survival and leukemic evolution in patients with myelodysplastic syndromeLuca Malcovati
Haematologica 91:1588-90. 2006
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot studyMario Cazzola
Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
Respir Med 101:957-62. 2007....
Microelectronic DNA chip for hereditary hyperferritinemia cataract syndrome, a model for large-scale analysis of disorders of iron metabolismFrancesca Ferrari
Unit of Genomics for Diagnosis of Human Pathologies, IRCCS H. San Raffaele, Milan, Italy
Hum Mutat 27:201-8. 2006..This pilot study represents a first step toward developing a diagnostic microchip for large-scale analyses for epidemiological studies and screening of mutations associated with iron disorders...
Further concerns about the medical risks of blood dopingMario Cazzola
Haematologica 87:232. 2002
Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitisMario Cazzola
Department of Pneumology, Unit of Pneumology and Allergology, A Cardarelli Hospital, Naples, Italy
Chest 128:2093-8. 2005....
Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infectionsMario Cazzola
Department of Respiratory Medicine, Unit of Pneumology and Allergology, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
Pulm Pharmacol Ther 16:131-45. 2003..Obviously, these antibiotics must be reserved only to cases of documented ineffectiveness of the common antimicrobial agents...
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patientsMario Cazzola
Antonio Cardarelli Hospital, Department of Respiratory Medicine, Unit of Pneumology and Allergology, Naples, Italy
Respir Med 99:524-8. 2005..Differences between the two treatments were not statistically significant (P>0.05). The addition of second different long-acting bronchodilator to a regularly administered long-acting bronchodilator seems to be to patient's advantage...
Prognostic relevance of anemia in myelodysplastic syndromesMario Cazzola
Am J Hematol 83:761-2. 2008
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsGhulam J Mufti
Department of Haematology, King s College Hospital, Denmark Hill, London, SE5 9RS United Kingdom
Haematologica 93:1712-7. 2008..Recommendations should be applied in the context of the WHO classification...
A gain-of-function mutation of JAK2 in myeloproliferative disordersRobert Kralovics
Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland
N Engl J Med 352:1779-90. 2005..The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases...
Somatic deletion of the normal beta-globin gene leading to thalassaemia intermedia in heterozygous beta-thalassaemic patientsRenzo Galanello
Dipartimento di Scienze Biomediche e Biotecnologie, Ospedale Microcitemico, University of Cagliari, 09121 Cagliari, Italy
Br J Haematol 127:604-6. 2004..This confirms that, in heterozygous individuals, beta-thalassaemia intermedia may be caused by inactivation of the beta-locus in trans as a result of chromosome 11p15.5 deletions in a subpopulation of haematopoietic cells...
Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosisMario Cazzola
Haematologica 92:1585-9. 2007
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPDMario Cazzola
Unit of Pneumology and Allergology, Department of Pneumology, A Cardarelli Hospital, Naples, Italy
Respiration 71:159-64. 2004....
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblastsJacqueline Boultwood
LRF Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
PLoS ONE 3:e1970. 2008..These data provide an important link between inherited and acquired forms of sideroblastic anemia and indicate that ABCB7 is a strong candidate gene for RARS...
Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary diseaseMario Cazzola
Department of Respiratory Medicine, A Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy
Expert Opin Investig Drugs 14:775-83. 2005..The only limits set for the development of a LABA with a new product profile are medical needs and marketing opportunities...
Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R)Antonella Roetto
Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Turin, Italy
Blood 103:2407-9. 2004..We identified a new mutation (C70R), which affects 1 of the 8 conserved cysteines that form the disulfide bonds and are critical for the stability of the polypeptide...
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyJohn Porter
University College London, London, UK
Eur J Haematol 80:168-76. 2008..Dosage was determined by baseline liver iron concentration (LIC)...
Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot studyFabiano Di Marco
Respiratory Medicine Unit, University of Milan, Ospedale San Paolo, Milano, Italy
Respir Med 100:1925-32. 2006....
